Skip To Main Content
Ethan S. Barnett on Muck Rack

Ethan S. Barnett

As seen in: Cell Press, European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ethan S.

Contact Ethan S., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer

|
By Ethan S. Barnett, Nikolaus Schultz, Konrad H. Stopsack, Ernest T Lam
| European Urology Verified
BRCA2 alterations predict for a response to poly-ADP-ribose polymerase inhibition in metastatic castration-resistant prostate cancer (mCRPC). However, detection is hindered by insufficient tumor tissue and low sensitivity of cell-free DNA for detecting copy number loss. To evaluate the BRCA2 loss detection using single-cell, shallow whole-genome sequencing (sWGS) of circulating tumor cells (CTCs) in patients with mCRPC.
Open in Who Shared Issue with article?

Optimizing the future: how mathematical models inform treatment schedules for cancer

|
By Deepti Mathur, Ethan S. Barnett, Howard I. Scher, João Xavier
| Cell Press Verified
Highlights For decades, mathematical models have influenced how we schedule chemotherapeutics: the most notable example stems from the Norton–Simon hypothesis which led to the advent of dose-dense scheduling to improve disease-free and overall survival. Newer mathematical models have leveraged game theory and ecological principles to propose adaptive therapy scheduling, with the aim of stabilizing a patient's disease and preventing the growth of surviving resistant cell populations.
Open in Who Shared Issue with article?

Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer

|
By Ryon P. Graf, Melanie Hullings, Ethan S. Barnett
| European Urology Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 CONSORT and treatment diagrams. (A) CONSORT diagram outlining samples used for propensity score and risk score generation and subset analyzed. (B) Flow diagram illustrating cohort treatment and AR-V7 testing history. The scoring criteria for AR-V7 positivity were prespecified, and the AR-V7 results were not released to physicians.
Open in Who Shared Issue with article?
See all 3 articles